©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2015; 21(39): 11016-11026
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11016
Published online Oct 21, 2015. doi: 10.3748/wjg.v21.i39.11016
Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation
Antonio Cuadrado, Javier Crespo, Emilio Fábrega, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, 39008 Santander, Cantabria, Spain
David San Segundo, Marcos López-Hoyos, Immunology Unit, Marqués de Valdecilla University Hospital. Instituto de Investigación Marqués de Valdecilla, 39008 Santander, Cantabria, Spain
Author contributions: Cuadrado A, San Segundo D, López-Hoyos M, Crespo J and Fábrega E analyzed the literature and wrote the manuscript.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Correspondence to: Dr. Emilio Fábrega, MD, PhD, Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, Avenida Valdecilla s/n, 39008 Santander, Cantabria. Spain. digfge@humv.es
Telephone: +34-73-442202544 Fax: +34-73-442202544
Received: April 18, 2015
Peer-review started: April 19, 2015
First decision: June 23, 2015
Revised: June 29, 2015
Accepted: September 13, 2015
Article in press: September 13, 2015
Published online: October 21, 2015
Processing time: 184 Days and 6.1 Hours
Peer-review started: April 19, 2015
First decision: June 23, 2015
Revised: June 29, 2015
Accepted: September 13, 2015
Article in press: September 13, 2015
Published online: October 21, 2015
Processing time: 184 Days and 6.1 Hours
Core Tip
Core tip: The role of donor-specific anti-human leukocyte antigen antibodies (DSA) in liver transplant (LT) remains unclear. Alloantibody-mediated adverse consequences are increasingly being recognized, and several cases of acute antibody-mediated rejection after ABO-compatible LT have been reported. There is a need to investigate and quantify the potential adverse impact of DSA on LT outcomes. The present review addresses the current knowledge on this issue.